THYMOSIN ALPHA-1 - Research Grade Peptide

THYMOSIN ALPHA-1 – Research-Grade N-Terminally Acetylated 28-Residue Peptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade, sequence-defined Thymosin Alpha-1 peptide with batch documentation available where supplied
• Defined linear structure comprising 28 amino-acid residues
• Covalently N-terminally acetylated peptide with a free C-terminal carboxylic acid
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content, molecular form and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

Thymosin Alpha-1, also known by the recognised substance name thymalfasin, is a sequence-defined 28-residue peptide containing a covalent N-terminal acetyl modification. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage, analytical method development and peptide characterisation. The stated nominal amount refers to the declared Thymosin Alpha-1 peptide content of a single vial, subject to the applicable batch documentation and stated assay basis.

Where dissolution or reconstitution is required, the solvent, buffer, concentration, mixing procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. A universal solvent instruction should not be applied to every molecular form, counter-ion presentation or formulated preparation. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: THYMOSIN ALPHA-1
• Preferred Substance Name: Thymalfasin
• Alternative Names: Thymosin Alpha-1; Thymosin α1; Tα1; Ta1; alpha-1 thymosin
• Material Classification: Synthetic N-terminally acetylated linear 28-residue peptide
• Sequence Length: 28 amino-acid residues
• Complete Modified Peptide Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
• Modified One-Letter Sequence: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH
• N-Terminal Structure: Covalently N-acetylated serine
• C-Terminal Structure: Free asparagine carboxylic acid terminus
• Acetylation Clarification: The N-terminal acetyl group forms part of the covalent peptide structure and is not an acetate counter-ion
• Cyclic or Linear Structure: Linear peptide
• Cysteine Content: None
• Disulphide-Bond Content: None; the Thymosin Alpha-1 sequence contains no cysteine residues
• Sulphur Content: None; the sequence contains neither cysteine nor methionine
• Parent Thymalfasin CAS Number: 62304-98-7
• PubChem Compound Identifier: CID 16130571
• Unique Ingredient Identifier: W0B22ISQ1C
• Parent Molecular Formula: C₁₂₉H₂₁₅N₃₃O₅₅
• Parent Average Molecular Weight: Approximately 3108.3 g/mol
• Approximate Molecular Size: 3.11 kDa
• Formula Basis: The molecular formula and molecular weight describe the parent N-terminally acetylated Thymosin Alpha-1 peptide without additional acetate, trifluoroacetate, sodium, residual water, solvents or formulation excipients
• Reference Thymosin Alpha-1 Acetate Formula: C₁₂₉H₂₁₅N₃₃O₅₅ · xCH₃COOH
• Thymosin Alpha-1 Acetate Molecular Weight: Dependent upon the measured acetate stoichiometry and other batch-specific components
• Acetate-Form Distinction: Thymosin Alpha-1 acetate is a supplied counter-ion form and should not be confused with the peptide’s covalent N-terminal acetyl modification
• CAS Number Qualification: CAS number 62304-98-7 identifies the parent thymalfasin molecular form; where suppliers apply this CAS number to an acetate-containing material, the acetate content should still be declared separately
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion should be stated in the batch Certificate of Analysis
• Purity Interpretation: Chromatographic purity represents the relative chromatographic composition measured under the stated analytical conditions and should not automatically be interpreted as equivalent to total net Thymosin Alpha-1 peptide content
• Peptide-Content Specification: Net Thymosin Alpha-1 content should be distinguished from chromatographic purity and interpreted alongside counter-ion content, water content, residual solvents and formulation components
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as parent thymalfasin peptide equivalent, total acetate-form material or total formulated lyophilised material
• Sequence Confirmation: The complete 28-residue amino-acid sequence should be confirmed using the applicable supplier, synthesis and batch records
• N-Terminal Acetylation Confirmation: Product identity should confirm the presence and position of the covalent N-terminal acetyl group using suitable mass-spectrometry or equivalent molecular-identity data
• C-Terminal Confirmation: Molecular-identity documentation should confirm the free C-terminal asparagine carboxylic acid structure
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the specified approximately 3108.3 Da parent Thymosin Alpha-1 structure
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied material is parent thymalfasin, Thymosin Alpha-1 acetate, a trifluoroacetate-containing form or another counter-ion presentation
• Counter-Ion Specification: Acetate, trifluoroacetate, sodium, ammonium or another counter-ion may affect the total supplied material mass and calculated net peptide content
• Acetate-Content Specification: Where acetate is present, its measured content and peptide-to-acetate relationship should be stated or supported by the applicable batch analytical documentation
• Water-Content Specification: Residual water may contribute to the total material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, purification, concentration and lyophilisation should be stated or controlled through the batch specification
• Aggregation Control: Aggregation and other concentration-dependent physical changes are separate quality attributes and are not established by a chromatographic purity percentage alone
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely acetylated material, incompletely deprotected sequences and other synthesis-related or process-related substances are separate quality attributes
• Dissolution Method: The appropriate solvent, buffer, concentration and mixing procedure should be selected using the applicable batch documentation and validated laboratory method; a universal bacteriostatic-water instruction should not be applied to every Thymosin Alpha-1 chemical form or preparation
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility. Sterility should only be claimed where supported by an appropriate validated sterility test and controlled filling process
• Analytical Interpretation: Molecular identity, amino-acid sequence, N-terminal acetylation, terminal structure, chromatographic purity, net peptide content, aggregation, water content, residual solvents, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete 28-residue amino-acid sequence should be confirmed using the applicable synthesis and batch records.
✓ N-terminal modification documentation – Covalent N-terminal acetylation should be supported by appropriate molecular-identity data.
✓ C-terminal structure documentation – The free C-terminal carboxylic acid structure should be confirmed using the applicable molecular-identity records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified Thymosin Alpha-1 structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net Thymosin Alpha-1 content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – Parent thymalfasin, acetate-containing, trifluoroacetate-containing or another counter-ion form should be identified clearly in the applicable product and batch records.
✓ Acetate-content documentation – Acetate identity, measured content and peptide-to-acetate relationship should be stated or supported where applicable.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

Thymosin Alpha-1 Product Overview

Our Thymosin Alpha-1 research-grade 28-residue peptide, also known by the recognised substance name thymalfasin, is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows and reference-material comparison.

Thymosin Alpha-1 comprises a defined linear sequence of 28 amino-acid residues with a covalently acetylated N-terminal serine and a free C-terminal asparagine carboxylic acid. The sequence contains no cysteine residues and therefore has no intramolecular disulphide bonds.

The CAS number 62304-98-7, molecular formula C₁₂₉H₂₁₅N₃₃O₅₅ and average molecular weight of approximately 3108.3 g/mol describe the parent thymalfasin peptide. Where the supplied laboratory material contains acetate, trifluoroacetate, sodium, residual water, solvents or formulation ingredients, the applicable batch documentation should identify their contribution to the total supplied material mass.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, amino-acid sequence, N-terminal acetylation, terminal structure, chromatographic purity, net peptide content, molecular form, counter-ion content, water content, residual solvents, aggregation, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The covalent N-terminal acetyl group should not be confused with acetate acting as a counter-ion. Where the product is supplied as Thymosin Alpha-1 acetate, the applicable product specification should state the measured acetate content and whether the nominal vial quantity represents parent thymalfasin peptide equivalent or total acetate-form material.

Chromatographic purity should not automatically be interpreted as equivalent to total net peptide content. Likewise, a bacterial endotoxin or lipopolysaccharide result does not establish sterility, molecular identity, correct N-terminal acetylation, sequence integrity or the absence of every peptide-related and process-related impurity.

For the majority of routine analytical, chromatographic, peptide-characterisation and general laboratory work, the Regular Thymosin Alpha-1 specification remains highly suitable. The premium black-and-gold ULTIMATE Thymosin Alpha-1 option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet